Pregabalin side effects: what 270,525 FDA adverse event reports show
Drug class
Not stated in label
Who reports
270,525 reports · 67% serious · 22,080 with death outcome · 66% female
Used for
Pregabalin capsules are indicated for: • Management of neuropathic pain associated with diabetic peripheral neuropathy • Management of postherpetic neuralgia • Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age an.
What it is
Pregabalin is a gamma-amino acid that is gamma-aminobutyric acid (GABA) carrying an isobutyl substitutent at the beta-position (the S-enantiomer).
Boxed warning
None in the current label
Causality screen of the 40 strongest signals
What the badges mean
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,131 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| C-reactive protein | 475 | 85.2 74.7–97.1ROR 85.3 · calibrated p 4e-7 ✓ | 40.5 EB05 37.5 · IC025 +5.1 3/3 methods agree | Lab value / disease marker | serious n=475 · ♀ 100% (drug 66%) · 100% clinician | not reported in cached trials |
| Deep vein thrombosis postoperative | 884 | 63.4 58.0–69.4ROR 63.6 · calibrated p 3e-6 ✓ | 34.9 EB05 33.0 · IC025 +5.0 3/3 methods agree | Not in label — unassessed | serious n=884 · ♀ 100% (drug 66%) · 100% clinician | not reported in cached trials |
| Lupus vulgaris | 472 | 50.7 45.1–56.9ROR 50.8 · calibrated p 1e-5 ✓ | 30.7 EB05 28.4 · IC025 +4.7 3/3 methods agree | Not in label — unassessed | serious n=472 · ♀ 100% (drug 66%) · 100% clinician | not reported in cached trials |
| Anti-cyclic citrullinated peptide antibody | 248 | 45.5 38.9–53.3ROR 45.6 · calibrated p 3e-5 ✓ | 28.7 EB05 25.8 · IC025 +4.6 3/3 methods agree | Lab value / disease marker | serious n=248 · ♀ 100% (drug 66%) · 100% clinician | not reported in cached trials |
| Swollen joint count increased | 1,077 | 40.6 37.7–43.7ROR 40.8 · calibrated p 5e-5 ✓ | 26.7 EB05 25.4 · IC025 +4.6 3/3 methods agree | Lab value / disease marker | serious n=1,076 · ♀ 100% (drug 66%) · 100% clinician | not reported in cached trials |
| Neurologic neglect syndrome | 176 | 35.2 29.5–42.1ROR 35.3 · calibrated p 1e-4 ✓ | 24.3 EB05 21.4 · IC025 +4.3 3/3 methods agree | Not in label — unassessed | serious n=176 · ♀ 100% (drug 66%) · 100% clinician | not reported in cached trials |
| Rheumatic fever | 1,154 | 27.6 25.8–29.5ROR 27.7 · calibrated p 4e-4 ✓ | 20.5 EB05 19.5 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=1,154 · ♀ 100% (drug 66%) · 95% clinician | not reported in cached trials |
| Facet joint syndrome | 798 | 26.0 24.0–28.2ROR 26.1 · calibrated p 5e-4 ✓ | 19.6 EB05 18.5 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=794 · ♀ 100% (drug 66%) · 93% clinician | not reported in cached trials |
| Adjustment disorder with depressed mood | 507 | 25.8 23.3–28.5ROR 25.9 · calibrated p 6e-4 ✓ | 19.5 EB05 18.1 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=501 · ♀ 100% (drug 66%) · 100% clinician | not reported in cached trials |
| Retinitis | 393 | 23.6 21.1–26.5ROR 23.7 · calibrated p 9e-4 ✓ | 18.2 EB05 16.8 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=393 · ♀ 100% (drug 66%) · 100% clinician | not reported in cached trials |
| X-ray abnormal | 412 | 23.0 20.6–25.7ROR 23.1 · calibrated p 0.001 ✓ | 17.9 EB05 16.5 · IC025 +4.0 3/3 methods agree | Lab value / disease marker | serious n=411 · ♀ 100% (drug 66%) · 100% clinician | not reported in cached trials |
| Amaurosis fugax | 240 | 22.2 19.2–25.6ROR 22.2 · calibrated p 0.001 ✓ | 17.4 EB05 15.6 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=240 · 100% clinician | not reported in cached trials |
| Substance use disorder | 681 | 21.8 20.0–23.8ROR 21.9 · calibrated p 0.001 ✓ | 17.1 EB05 16.1 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=680 · ♀ 20% (drug 66%) · 100% clinician | not reported in cached trials |
| Carotid artery thrombosis | 189 | 21.8 18.6–25.6ROR 21.8 · calibrated p 0.001 ✓ | 17.1 EB05 15.2 · IC025 +3.8 3/3 methods agree | Not in label — unassessed | serious n=189 · ♀ 100% (drug 66%) · 100% clinician | not reported in cached trials |
| Dislocation of vertebra | 478 | 21.0 19.0–23.2ROR 21.0 · calibrated p 0.002 ✓ | 16.6 EB05 15.4 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=478 · ♀ 100% (drug 66%) · 100% clinician | not reported in cached trials |
| Rheumatoid factor positive | 1,217 | 20.5 19.3–21.9ROR 20.6 · calibrated p 0.002 ✓ | 16.3 EB05 15.6 · IC025 +3.9 3/3 methods agree | Lab value / disease marker | serious n=1,216 · ♀ 100% (drug 66%) · 95% clinician | not reported in cached trials |
| Duodenal ulcer perforation | 1,290 | 16.3 15.4–17.4ROR 16.4 · calibrated p 0.005 ✓ | 13.6 EB05 13.0 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious PRR 11.7 · ♀ 100% (drug 66%) · 95% clinician | not reported in cached trials |
| Seronegative arthritis | 191 | 15.7 13.5–18.4ROR 15.7 · calibrated p 0.006 ✓ | 13.1 EB05 11.6 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious n=191 · ♀ 100% (drug 66%) · 100% clinician | not reported in cached trials |
| C-reactive protein abnormal | 1,081 | 15.6 14.6–16.6ROR 15.6 · calibrated p 0.006 ✓ | 13.1 EB05 12.4 · IC025 +3.6 3/3 methods agree | Lab value / disease marker | serious n=1,079 · 91% clinician | not reported in cached trials |
| Pre-existing condition improved | 1,030 | 15.0 14.0–16.0ROR 15.0 · calibrated p 0.007 ✓ | 12.6 EB05 12.0 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious n=361 | not reported in cached trials |
| Fibromyalgia | 3,952 | 14.9 14.4–15.4ROR 15.1 · calibrated p 0.007 ✓ | 12.6 EB05 12.3 · IC025 +3.6 3/3 methods agree | Likely indication confounding term in indications; also in warnings | serious PRR 11.3 · ♀ 92% (drug 66%) | not reported in cached trials |
| Adjustment disorder | 204 | 14.2 12.2–16.5ROR 14.2 · calibrated p 0.009 ✓ | 12.1 EB05 10.7 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious n=199 · ♀ 100% (drug 66%) · 100% clinician | not reported in cached trials |
| Drug use disorder | 1,284 | 14.1 13.3–14.9ROR 14.1 · calibrated p 0.009 ✓ | 12.0 EB05 11.5 · IC025 +3.5 3/3 methods agree | Labeled (related wording) related wording | serious PRR 10.7 · ♀ 24% (drug 66%) · 100% clinician | NCT01256593: 1/3,613 (0.0%) on Pregabalin (serious AE) |
| Sleep disorder due to general medical condition, insomnia type | 977 | 13.7 12.8–14.7ROR 13.8 · calibrated p 0.010 ✓ | 11.7 EB05 11.1 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious n=972 · ♀ 100% (drug 66%) · 100% clinician | not reported in cached trials |
| Porphyria acute | 206 | 13.4 11.6–15.6ROR 13.4 · calibrated p 0.011 ✓ | 11.5 EB05 10.2 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious n=206 · ♀ 100% (drug 66%) · 100% clinician | not reported in cached trials |
| Helicobacter infection | 1,389 | 12.1 11.4–12.8ROR 12.1 · calibrated p 0.016 ✓ | 10.5 EB05 10.1 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious PRR 9.6 · ♀ 100% (drug 66%) · 92% clinician | not reported in cached trials |
| Sciatica | 2,115 | 11.8 11.3–12.3ROR 11.9 · calibrated p 0.017 ✓ | 10.3 EB05 10.0 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious PRR 11.1 · ♀ 91% (drug 66%) | NCT01256593: 1/3,613 (0.0%) on Pregabalin |
| Personality disorder | 338 | 11.3 10.1–12.6ROR 11.3 · calibrated p 0.021 ✓ | 9.9 EB05 9.0 · IC025 +3.1 3/3 methods agree | Labeled adverse reaction exact term | serious n=330 · ♀ 100% (drug 66%) | not reported in cached trials |
| Muscle injury | 1,028 | 11.0 10.3–11.7ROR 11.0 · calibrated p 0.023 ✓ | 9.7 EB05 9.2 · IC025 +3.2 3/3 methods agree | Labeled (related wording) related wording | serious PRR 9.0 · ♀ 100% (drug 66%) · 91% clinician | not reported in cached trials |
| Bone erosion | 426 | 10.5 9.5–11.6ROR 10.5 · calibrated p 0.028 ✓ | 9.3 EB05 8.5 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious n=425 · ♀ 100% (drug 66%) · 100% clinician | not reported in cached trials |
| Post herpetic neuralgia | 172 | 10.4 8.9–12.2ROR 10.4 · calibrated p 0.029 ✓ | 9.1 EB05 8.0 · IC025 +2.9 3/3 methods agree | Likely indication confounding term in indications; also in warnings | ♀ 0% (drug 66%) · 100% consumer | not reported in cached trials |
| Feeling drunk | 884 | 10.3 9.6–11.0ROR 10.3 · calibrated p 0.029 ✓ | 9.2 EB05 8.7 · IC025 +3.1 3/3 methods agree | Labeled adverse reaction exact term | serious n=512 | not reported in cached trials |
| Anti-cyclic citrullinated peptide antibody positive | 838 | 10.2 9.5–11.0ROR 10.3 · calibrated p 0.030 ✓ | 9.1 EB05 8.6 · IC025 +3.1 3/3 methods agree | Lab value / disease marker | serious PRR 7.9 · ♀ 100% (drug 66%) · 93% clinician | not reported in cached trials |
| Folliculitis | 1,208 | 10.1 9.6–10.8ROR 10.2 · calibrated p 0.030 ✓ | 9.0 EB05 8.6 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious PRR 9.1 · ♀ 100% (drug 66%) · 95% clinician | NCT01256593: 1/3,613 (0.0%) on Pregabalin |
| Peripheral venous disease | 455 | 9.8 8.9–10.9ROR 9.9 · calibrated p 0.034 ✓ | 8.8 EB05 8.1 · IC025 +3.0 3/3 methods agree | Labeled (related wording) related wording | serious n=448 · ♀ 100% (drug 66%) · 100% clinician | not reported in cached trials |
| Diabetic neuropathy | 558 | 9.7 8.9–10.6ROR 9.7 · calibrated p 0.036 ✓ | 8.6 EB05 8.1 · IC025 +3.0 3/3 methods agree | Labeled adverse reaction exact term | serious n=399 | not reported in cached trials |
| Drug tolerance decreased | 312 | 9.6 8.5–10.8ROR 9.6 · calibrated p 0.037 ✓ | 8.6 EB05 7.8 · IC025 +2.9 3/3 methods agree | Labeled (related wording) related wording | serious n=303 · ♀ 100% (drug 66%) · 100% clinician | not reported in cached trials |
| Bradypnoea | 288 | 9.2 8.1–10.4ROR 9.2 · calibrated p 0.043 ✓ | 8.2 EB05 7.5 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious n=288 · ♀ 39% (drug 66%) · 100% clinician | not reported in cached trials |
| Radiculopathy | 280 | 9.1 8.0–10.3ROR 9.1 · calibrated p 0.045 ✓ | 8.2 EB05 7.4 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious n=264 · ♀ 100% (drug 66%) | NCT01256593: 1/3,613 (0.0%) on Pregabalin (serious AE) |
| Autoimmune disorder | 1,014 | 9.1 8.5–9.7ROR 9.1 · calibrated p 0.044 ✓ | 8.2 EB05 7.8 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | serious PRR 7.6 · ♀ 100% (drug 66%) | not reported in cached trials |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Dependence / withdrawal | 9,728 | 2.62.6–2.7 | signal |
| Fall / fracture | 11,665 | 2.42.4–2.5 | signal |
| Depression | 8,150 | 2.32.2–2.3 | signal |
| Suicidality | 7,024 | 2.32.2–2.3 | signal |
| Interstitial lung disease | 2,705 | 2.22.1–2.3 | signal |
| Extrapyramidal | 2,533 | 1.91.8–2.0 | raised |
| Rhabdomyolysis / myopathy | 1,833 | 1.81.7–1.9 | raised |
| Hyponatraemia | 1,754 | 1.71.6–1.8 | raised |
| Seizure | 4,184 | 1.71.6–1.7 | raised |
| Opportunistic infection | 2,861 | 1.61.6–1.7 | raised |
| Serious infection | 16,203 | 1.61.6–1.7 | raised |
| Liver injury | 5,987 | 1.51.5–1.6 | raised |
| Kidney injury | 8,531 | 1.51.4–1.5 | raised |
| Hyperglycaemia / diabetes | 6,367 | 1.41.4–1.5 | raised |
| Tendon disorder | 679 | 1.41.3–1.5 | raised |
| Hypoglycaemia | 1,541 | 1.31.2–1.3 | raised |
Trial evidence (ClinicalTrials.gov)
✓ Trial adverse-event data found on ClinicalTrials.gov
Largest completed trials with posted results that list Pregabalin as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (4 of 40 signal terms matched).
- NCT01220180 — Lyrica (Pregabalin) Korean Post Marketing Surveillance Study (N=4175, phase n/a; 49 AE terms posted; arms: Pregabalin)
- NCT01256593 — Safety And Efficacy Of Lyrica (Regulatory Post Marketing Commitment Plan) (N=3827, phase n/a; 223 AE terms posted; arms: LYRICA Capsules (Pregabalin))
Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Drug ineffective (drug did not work) | 26,977 | 1.6 1.6–1.6ROR 1.7 · calibrated p 0.749 | 1.6 EB05 1.6 · IC025 +0.6 | Reporting / coding artifact | age-adj. PRR 1.8 · serious PRR 2.0 | not reported in cached trials |
| Pain | 26,331 | 3.4 3.4–3.5ROR 3.7 · calibrated p 0.442 | 3.3 EB05 3.3 · IC025 +1.7 3/3 methods agree | Likely indication confounding term in indications; also in warnings | age-adj. PRR 3.5 · serious PRR 2.6 | NCT01220180: 2/4,174 (0.0%) on Pregabalin |
| Fatigue (tiredness) | 15,635 | 1.6 1.5–1.6ROR 1.6 · calibrated p 0.710 | 1.6 EB05 1.5 · IC025 +0.6 | Labeled adverse reaction exact term | age-adj. PRR 1.5 · serious PRR 1.9 | NCT01220180: 3/4,174 (0.1%) on Pregabalin |
| Dizziness | 14,847 | 2.4 2.3–2.4ROR 2.4 · calibrated p 0.843 | 2.3 EB05 2.3 · IC025 +1.2 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.0 · serious PRR 2.4 | NCT01220180: 74/4,174 (1.8%) on Pregabalin |
| Nausea | 14,509 | 1.4 1.4–1.5ROR 1.5 · calibrated p 0.614 | 1.4 EB05 1.4 · IC025 +0.5 | Labeled adverse reaction exact term | age-adj. PRR 1.3 · serious PRR 1.8 | NCT01256593: 27/3,613 (0.7%) on Pregabalin |
| Off label use (used outside approved label) | 13,801 | 1.2 1.2–1.3ROR 1.2 · calibrated p 0.473 | 1.2 EB05 1.2 · IC025 +0.3 | Reporting / coding artifact | age-adj. PRR 1.4 · serious PRR 1.5 | not reported in cached trials |
| Headache | 13,069 | 1.6 1.6–1.7ROR 1.7 · calibrated p 0.746 | 1.6 EB05 1.6 · IC025 +0.7 | Labeled adverse reaction exact term | age-adj. PRR 1.5 · serious PRR 2.1 | NCT01220180: 1/4,174 (0.0%) on Pregabalin |
| Malaise (feeling unwell) | 12,884 | 2.3 2.3–2.4ROR 2.4 · calibrated p 0.868 | 2.3 EB05 2.2 · IC025 +1.2 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.3 · serious PRR 2.2 | NCT01256593: 4/3,613 (0.1%) on Pregabalin |
| Somnolence (drowsiness) | 11,823 | 4.8 4.7–4.9ROR 5.0 · calibrated p 0.239 | 4.6 EB05 4.5 · IC025 +2.2 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 4.4 · serious PRR 4.6 | NCT01220180: 69/4,174 (1.7%) on Pregabalin |
| Weight increased (weight gain) | 11,621 | 4.2 4.1–4.3ROR 4.4 · calibrated p 0.317 | 4.0 EB05 4.0 · IC025 +2.0 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 3.6 · serious PRR 4.1 | NCT01220180: 1/4,174 (0.0%) on Pregabalin |
| Pain in extremity | 11,394 | 3.1 3.0–3.1ROR 3.2 · calibrated p 0.575 | 3.0 EB05 2.9 · IC025 +1.5 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.7 · serious PRR 3.0 | NCT01256593: 2/3,613 (0.1%) on Pregabalin |
| Fall | 11,040 | 2.6 2.6–2.7ROR 2.7 · calibrated p 0.733 | 2.6 EB05 2.5 · IC025 +1.3 3/3 methods agree | Not in label — unassessed | age-adj. PRR 2.4 · serious PRR 2.4 | NCT01256593: 4/3,613 (0.1%) on Pregabalin (serious AE) |
| Dyspnoea (shortness of breath) | 10,459 | 1.4 1.4–1.5ROR 1.5 · calibrated p 0.615 | 1.4 EB05 1.4 · IC025 +0.5 | Labeled adverse reaction exact term | age-adj. PRR 1.3 · serious PRR 1.5 | not reported in cached trials |
| Diarrhoea (diarrhea) | 10,172 | 1.2 1.2–1.3ROR 1.2 · calibrated p 0.466 | 1.2 EB05 1.2 · IC025 +0.3 | Labeled adverse reaction exact term | age-adj. PRR 1.1 · serious PRR 1.4 | NCT01220180: 1/4,174 (0.0%) on Pregabalin |
| Insomnia (trouble sleeping) | 9,729 | 2.9 2.8–3.0ROR 3.0 · calibrated p 0.637 | 2.8 EB05 2.8 · IC025 +1.5 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.8 · serious PRR 3.0 | NCT01220180: 1/4,174 (0.0%) on Pregabalin |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Deep vein thrombosis postoperative — n=884, PRR 63.4
- Lupus vulgaris — n=472, PRR 50.7
- Neurologic neglect syndrome — n=176, PRR 35.2
- Rheumatic fever — n=1,154, PRR 27.6
- Facet joint syndrome — n=798, PRR 26.0
- Adjustment disorder with depressed mood — n=507, PRR 25.8
- Retinitis — n=393, PRR 23.6
- Amaurosis fugax — n=240, PRR 22.2
- Substance use disorder — n=681, PRR 21.8
- Carotid artery thrombosis — n=189, PRR 21.8
✓ A hand-written Bradford Hill causality assessment exists for this drug: Pregabalin ↔ Oedema peripheral.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Pregabalin?
In FDA FAERS, the most frequently co-reported reaction terms for Pregabalin are pain, fatigue, dizziness, nausea, headache, malaise. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Pregabalin have an FDA boxed warning?
No. The FDA label retrieved for Pregabalin has no boxed warning; see the label's Warnings and Precautions for the recognised risks.
Do FAERS signals prove that Pregabalin causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 085db834-3735-40d9-ac67-f9dbb82390c5, effective 20260319; matched on
openfda.generic_name.exact:"PREGABALIN" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - PubChem CID 5486971 description (ChEBI)
- Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,171 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
PREGABALIN, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.